Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 44, Issue 5, Pages 959-966Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2004.05.070
Keywords
-
Categories
Ask authors/readers for more resources
Anemia has recently been recognized as an important comorbid condition and potentially novel therapeutic target in patients with heart failure (HF). Anemia is common in HF patients, with a prevalence ranging from 4% to 55% depending on the population studied. Multiple potential mechanisms of interaction exist between anemia and the clinical syndrome of HF, including hemodilution, inflammatory activation, renal insufficiency, and malnutrition. A growing body of literature from observational databases and clinical trials suggests that anemia is an independent risk factor for adverse outcomes in patients with HF. Although preliminary data suggest that treatment of anemia may result in significant symptomatic improvement in HF, aggressive treatment of anemia may also be associated with increased risk of hypertension or thrombosis. Multiple ongoing studies win provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF. (C) 2004 by the American College of Cardiology Foundation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available